Leman's new heart valve beats rival products
This article was originally published in Clinica
Executive Summary
Animal studies have shown that Leman Cardiovascular's third-generation heart valve performs better than rival products. The way is now clear for human trials, due "in early 2008", said CEO Benedict Broennimann.
You may also be interested in...
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Biogen And Sage On Plans To Build A Brain Franchise Together
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: